Myrtelle Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles River and Viralgen

Team prepares for commercialization bolstered by START Program and regulatory recognition NEW YORK, July 8, 2025 /PRNewswire/ -- Myrtelle Inc. ("Myrtelle" or the "Company"), a pioneering clinical-stage gene therapy company dedicated to revolutionizing treatment for neurodegenerative...